Form 4: Acrivon Therapeutics Executive Reports Stock Transactions
SEC Form 4 Filing
Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, reports the disposal of shares to cover tax obligations and disclaims beneficial ownership of shares held by her spouse, the company's CEO.
Summary
- On May 14, 2024, Kristina Masson, EVP of Business Operations at Acrivon Therapeutics, reported a transaction involving common stock.
- 490 shares were disposed of at a price of $8.36 to satisfy tax withholding requirements upon vesting of restricted stock units.
- Following the transaction, Masson directly owns 317,736 shares of common stock.
- Masson also disclaims beneficial ownership of 2,561,894 shares held by her spouse, Peter Blume-Jensen, the President and CEO of Acrivon Therapeutics, except to the extent of her pecuniary interest.
Sentiment
Score: 5
Explanation: This is a neutral filing related to stock transactions for tax purposes. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This is a routine Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It provides transparency to the market regarding insider activity.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine disposal of shares for tax purposes.
Key Dates
| Date | Description |
|---|---|
| 05/14/2024 | Date of stock transaction (disposal of shares for tax withholding). |
| 05/16/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.